drugset / Press release
Ultragenyx Receives Approval of Clinical Trial Application (CTA) for a Phase 1/2 Trial Testing UX003 in Mucopolysaccharidosis Type 7 (MPS 7)
2013-08-14 · Ultragenyx Pharmaceutical Inc · original ultragenyx.com ↗
Ultragenyx Receives Approval of Clinical Trial Application (CTA) for a Phase 1/2 Trial Testing UX003 in Mucopolysaccharidosis Type 7 (MPS 7)
The release as fetched from its publisher. ultragenyx.com ↗